Diabetic Retinopathy News and Research

RSS
In the initial stages, people with diabetic retinopathy may not notice their vision changing. Diabetics sometimes experience rapid changes in blood sugar that can temporarily cause blurry vision even when retinopathy is not present. If a person notices a few specks or spots floating in his visual field, this may mean he has developed proliferative diabetic retinopathy, the growth of abnormal new blood vessels on the retina and optic nerve. High blood sugar levels have been linked in studies to retinal blood vessel abnormalities. Blurred vision may occur when the macula--the small area at the center of the retina--swells as it fills with fluid that has leaked from retinal blood vessels. Because damage to the eye often develops slowly, early detection of diabetes and control of blood sugar through diet and medications can make a crucial difference in saving vision.

Effective diabetic retinopathy treatments include laser photocoagulation for early to moderate stages and a microsurgery called vitrectomy for repair of eyes with extensive damage. Injectable and oral medications that act on abnormal blood vessels to control diabetic retinopathy before vision loss occurs are now in development. Early detection would be key to the effectiveness of these treatments, also.
Researchers report progress on two eye disease challenges at AAO-MEACO 2010 Joint Meeting

Researchers report progress on two eye disease challenges at AAO-MEACO 2010 Joint Meeting

Childrens Hospital Los Angeles receives $1M NCI grant for eye port clinical trial to treat retinoblastoma in children

Childrens Hospital Los Angeles receives $1M NCI grant for eye port clinical trial to treat retinoblastoma in children

Alimera to present Iluvien Phase 3 clinical trial data at AAO annual meeting

Alimera to present Iluvien Phase 3 clinical trial data at AAO annual meeting

Medicare recipients receiving treatment for retinal condition increases with shifts in procedure

Medicare recipients receiving treatment for retinal condition increases with shifts in procedure

MingSight acquires worldwide rights from Pfizer to develop new chemical entities for human diseases

MingSight acquires worldwide rights from Pfizer to develop new chemical entities for human diseases

IRIDEX announces commercial availability of extended EndoProbe laser delivery device family in Japan

IRIDEX announces commercial availability of extended EndoProbe laser delivery device family in Japan

Six3 gene safeguards future retina

Six3 gene safeguards future retina

AstraZeneca, UCL collaborate to identify new therapeutic tools to modulate regenerative capacity of stem cells

AstraZeneca, UCL collaborate to identify new therapeutic tools to modulate regenerative capacity of stem cells

Multispectral imaging of ocular fundus using new LED Illumination system

Multispectral imaging of ocular fundus using new LED Illumination system

FDA grants Priority Review status to Alimera Sciences' Iluvien for diabetic macular edema

FDA grants Priority Review status to Alimera Sciences' Iluvien for diabetic macular edema

USPTO grants IRIDEX patent for MicroPulse technology in laser eye surgery

USPTO grants IRIDEX patent for MicroPulse technology in laser eye surgery

Alimera Sciences second-quarter net loss decreases to $4.8 million

Alimera Sciences second-quarter net loss decreases to $4.8 million

Survey finds prevalence of diabetic retinopathy high among U.S. adults

Survey finds prevalence of diabetic retinopathy high among U.S. adults

Scientific paper explains impact of visual cycle modulation in neurovascular retinopathy

Scientific paper explains impact of visual cycle modulation in neurovascular retinopathy

Ampio finalizes negotiations to acquire DMI BioSciences

Ampio finalizes negotiations to acquire DMI BioSciences

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

Ampio Pharmaceuticals commences Optina Phase II clinical trial for diabetic macular edema

Ampio Pharmaceuticals commences Optina Phase II clinical trial for diabetic macular edema

California companies are developing new medicines for diabetes: Report

California companies are developing new medicines for diabetes: Report

Alimera Sciences submits MAA for Iluvien to MHRA

Alimera Sciences submits MAA for Iluvien to MHRA

ThromboGenics to present microplasmin Phase III trial data at 28th ASRS and 10th EURETINA Congress

ThromboGenics to present microplasmin Phase III trial data at 28th ASRS and 10th EURETINA Congress

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.